• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail

Symbyax (olanzapine and fluoxetine HCl)

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – September 2011

 

Summary View

 

ADVERSE REACTIONS

Additional Findings Observed in Clinical Studies

Sexual Dysfunction

  • There are no adequate and well-controlled studies examining sexual dysfunction with Symbyax or fluoxetine treatment. Symptoms of sexual dysfunction occasionally persist after discontinuation of fluoxetine treatment...